Bristol-Myers Squibb (BMY) Tops Q3 EPS by 22c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Bristol-Myers Squibb (BMY) Tops Q3 EPS by 22c, Offers Guidance

Bristol Myers Squibb Reports Third Quarter Financial Results for 2023

October 26, 2023 6:59 AM EDT

Reports Third Quarter Revenues of $11.0 Billion Posts Third Quarter GAAP Earnings Per Share of $0.93 and Non-GAAP EPS of $2.00; Includes Net Impact of ($0.03) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income Reports Third Quarter Revenue Growth for In-Line Products and New Product Portfolio of 8%, or 7% When Adjusted for Foreign Exchange Achieves Key Clinical and Regulatory Milestones Across Multiple Therapeutic Areas Strengthens Oncology Portfolio with Planned Acquisition of Targeted Oncology Company Mirati Therapeutics Adjusts 2023 GAAP EPS Guidance; Raises Midpoint of... More